Patents by Inventor Thomas E. Prisinzano

Thomas E. Prisinzano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agonists of the mu opioid receptor
    Patent number: 11034679
    Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists of Formula I. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: June 15, 2021
    Assignees: UNIVERSITY OF KANSAS, VICTORIA LINK LIMITED
    Inventors: Thomas E. Prisinzano, Rachel Saylor Crowley, Bronwyn Maree Daken Kivell
  • AGONISTS OF THE MU OPIOID RECEPTOR
    Publication number: 20200385368
    Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
    Type: Application
    Filed: November 14, 2018
    Publication date: December 10, 2020
    Applicants: UNIVERSITY OF KANSAS, VICTORIA LINK LIMITED
    Inventors: Thomas E. Prisinzano, Rachel Saylor Crowley, Bronwyn Maree Daken
  • Agonists of the mu opioid receptor
    Patent number: 10125129
    Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor over the kappa opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: November 13, 2018
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Thomas E. Prisinzano, Andrew P. Riley, Chad E. Groer
  • Kappa opioid receptor selective compounds, compositions, and uses thereof
    Patent number: 9868730
    Abstract: The present invention provides, inter alia, compounds of formula (I): (structurally represented). Also provided are pharmaceutical compositions containing such compounds and methods for treating or ameliorating the effects of a medical condition in a subject using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: January 16, 2018
    Assignees: The Trustees of Columbia University in the City of New York, Icahn School of Medicine at Mount Sinai
    Inventors: Jonathan Javitch, Marie-Laure Rives, Marta Filizola, Thomas E. Prisinzano
  • AGONISTS OF THE MU OPIOID RECEPTOR
    Publication number: 20170313692
    Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor over the kappa opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
    Type: Application
    Filed: April 27, 2017
    Publication date: November 2, 2017
    Inventors: Thomas E. Prisinzano, Andrew P. Riley, Chad E. Groer
  • Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases
    Patent number: 9416103
    Abstract: Novel alkylindoles that bind tightly to cannabinoid receptors and are neutral antagonists for the cannabinoid 1 receptor and agonists for the cannabinoid 2 receptor are provided. These compounds are useful for treating alcoholism and drug abuse and for treating obesity.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: August 16, 2016
    Assignees: The Board of Trustees of the University of Arkansas, The University of Kansas
    Inventors: Paul L. Prather, Thomas E. Prisinzano, William E. Fantegrossi, Lisa K. Brents, Jeffery Moran, Anna Radominska-Pandya, Tamara Vasiljevik
  • KAPPA OPIOID RECEPTOR SELECTIVE COMPOUNDS, COMPOSITIONS, AND USES THEREOF
    Publication number: 20160002216
    Abstract: The present invention provides, inter alia, compounds of formula (I): (structurally represented). Also provided are pharmaceutical compositions containing such compounds and methods for treating or ameliorating the effects of a medical condition in a subject using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: February 14, 2014
    Publication date: January 7, 2016
    Inventors: Jonathan JAVITCH, Marie-Laure RIVES, Marta FILIZOLA, Thomas E, PRISINZANO
  • USE OF THE AMINOALKYLINDOLE JWH-073-M4 AND RELATED COMPOUNDS AS NEUTRAL CB1 RECPTOR ANTAGONISTS FOR THE TREATMENT OF ALCOHOLISM, DRUG ABUSE, OBESITY, AND OBESITY-RELATED DISEASES
    Publication number: 20150266820
    Abstract: Novel alkylindoles that bind tightly to cannabinoid receptors and are neutral antagonists for the cannabinoid 1 receptor and agonists for the cannabinoid 2 receptor are provided. These compounds are useful for treating alcoholism and drug abuse and for treating obesity.
    Type: Application
    Filed: January 8, 2013
    Publication date: September 24, 2015
    Inventors: Paul L. Prather, Thomas E. Prisinzano, William E. Fantegrossi, Lisa K. Brents, Jefferey Moran, Anna Radominska-Pandya, Tamara Vasiljevik
  • OPIOID RECEPTOR LIGANDS
    Publication number: 20090088466
    Abstract: The invention provides novel compounds of formula (I), (II), (III), and (IV). The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to an animal in need of treatment. The invention also provides therapeutic methods for the use of compounds of formula (V), as well as methods for treating diseases by administering such compounds.
    Type: Application
    Filed: June 16, 2006
    Publication date: April 2, 2009
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Laura M. Bohn, Thomas E. Prisinzano